TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab
19 Mai 2023 - 1:00PM
TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical
technology company focused on providing innovative technologies
that optimize clinical outcomes by prioritizing the preservation
and restoration of the patient’s own anatomy, today announced it
will be hosting its next cadaver lab on May 19 in Tampa, Florida.
The upcoming program, “Advanced Hernia Repair with OviTex®
Reinforced Tissue Matrix,” will provide surgeons the opportunity to
learn innovative open and robotic-assisted hernia repair
techniques.
TELA Bio has partnered with key opinion leaders in general and
plastic and reconstructive surgery to develop a series of
interactive medical education programs focused on the safe and
effective use of OviTex in a variety of hernia repair techniques.
Since the beginning of 2023, the company has conducted 98 medical
education programs, including national and regional cadaveric labs,
surgical observations, and various virtual education programs. The
company’s growing investment in customer education demonstrates its
commitment to improving patient outcomes.
“TELA Bio's dedication to providing continued education is
essential in advancing the practice of hernia repair,” said Rodolfo
J. Oviedo, MD, FACS, FASMBS, FICS, FPDMBS, Director of Robotic
General Surgery at Houston Methodist, Texas Medical Center. “The
ability to share and learn effective techniques with OviTex is
important for surgeons interested in employing these technological
advancements for optimized patient care.”
Surgeons, ranging from residents to those with decades of
experience, will convene at this event to explore the latest in
hernia repair material and techniques. The programs are carefully
designed to offer a tailored educational approach, meeting the
training needs for each individual participant. The attendees will
learn how to use OviTex for hernia repair through open and robotic
procedures, allowing them to adopt the approaches that work best
for their practices and elevate the quality of patient care.
“Our commitment to education, research, and innovation is what
sets TELA Bio apart from others in the industry,” said Jane Tuohy,
Vice President, Program Marketing and Medical Education. “We will
continue to prioritize providing high impact training and education
to support the needs of the surgeon community, and we’re proud to
offer a range of educational opportunities, from virtual training
events to hands-on cadaver labs, to help them stay up-to-date on
the latest techniques and technologies. Our upcoming lab featuring
OviTex, and robotic-assisted procedures is just one example of our
dedication to advancing hernia repair surgery.”
About TELA Bio, Inc.TELA Bio, Inc. is a
commercial-stage medical technology company focused on providing
innovative technologies that optimize clinical outcomes by
prioritizing the preservation and restoration of the patient's own
anatomy. The Company is committed to providing surgeons with
advanced, economically effective soft-tissue reconstruction
solutions that leverage the patient's natural healing response
while minimizing long-term exposure to permanent synthetic
materials. For more information, visit www.telabio.com.
About OviTexOviTex Reinforced Tissue Matrix is
intended for use as a surgical mesh to reinforce and/or repair soft
tissue where weakness exists. Indications for use include the
repair of hernias and/or abdominal wall defects that require the
use of reinforcing or bridging material to obtain the desired
surgical outcome. Do not use OviTex in patients known to be
sensitive to materials of ovine (sheep) origin. For prescription
use only. For additional important safety information, please see
the OviTex Reinforced Tissue Matrix Instructions for Use.
Caution Regarding
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Words such as "may," "might," "will," "should," "believe,"
"expect," "anticipate," "estimate," "continue," "predict,"
"forecast," "project," "plan," "intend" or similar expressions, or
statements regarding intent, belief, or current expectations are
forward-looking statements and reflect the current beliefs of TELA
Bio's management. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties and
other factors that could cause actual results and events to differ
materially and adversely from those indicated by such
forward-looking statements. These risks and uncertainties are
described more fully in the "Risk Factors" section and elsewhere in
our filings with the Securities and Exchange Commission and
available at www.sec.gov, including in our Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q. Any
forward-looking statements that we make in this announcement speak
only as of the date of this press release, and TELA Bio assumes no
obligation to update forward-looking statements whether as a result
of new information, future events or otherwise after the date of
this press release, except as required under applicable law.
Investor ContactGreg
Chodaczek347-620-7010ir@telabio.com
Media ContactAlyson
Kuritz908-892-7149alyson@0to5.com
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
Von Mai 2023 bis Mai 2024